US › Healthcare

Arvinas Inc (ARVN)

US · Healthcare · Biotechnology

$8.31+1.84%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$249.7M

Revenue YoY

+1014.7%

Net profit

$169.4M

EPS

$2.58

EPS estimate

$-0.24

Net margin

67.8%

EPS came in at 2.58 against a street estimate of -0.24 — a beat of 1175.0%.

Key statistics

Market cap

$532.9M

P/E

31.8

Forward P/E

17.9

P/B

0.98

Book value

$8.61

EPS (TTM)

$0.26

52-week high

$14.51

52-week low

$6.97

50-day MA

$8.72

200-day MA

$10.46

Beta

1.76

Analyst view

Analysts rate Arvinas Inc a buy (13 buy, 8 hold, 0 sell out of 21) with an average price target of $13.93.

Shareholding

Insiders

7.80%

Institutions

84.21%

Largest institutional holders

Fund	Stake
BlackRock Inc	10.40%
Vanguard Portfolio Management, LLC	5.95%
D. E. Shaw & Co LP	5.35%
Pfizer Inc	5.29%
Vanguard Capital Management, LLC	4.11%
Armistice Capital, LLC	3.03%
Two Sigma Investments LLC	2.80%
State Street Corp	2.80%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Arvinas Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.